Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 EUR | -0.91% |
|
+5.29% | -16.57% |
Jul. 01 | Akeso, Inc. Announces Change of Directors | CI |
Jun. 04 | Akeso Expands Territory of License Agreement for Lung Cancer Drug | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.57% | 4.19B | - | ||
+15.82% | 121B | B+ | ||
+20.35% | 113B | B+ | ||
+17.47% | 26.02B | B | ||
-25.31% | 19.39B | B+ | ||
-19.51% | 15.91B | A- | ||
-19.67% | 15.09B | B | ||
-46.87% | 15.06B | A- | ||
+62.55% | 14.93B | C+ | ||
+6.34% | 13.85B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 9926 Stock
- 4RY Stock
- Ratings Akeso, Inc.